CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.860
EU - Europa 5.186
AS - Asia 1.349
AF - Africa 259
SA - Sud America 37
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.702
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.731
DE - Germania 2.039
IT - Italia 1.013
SE - Svezia 817
CN - Cina 575
GB - Regno Unito 452
SG - Singapore 359
BG - Bulgaria 270
AT - Austria 219
CI - Costa d'Avorio 146
TR - Turchia 127
CA - Canada 123
SN - Senegal 104
RU - Federazione Russa 103
VN - Vietnam 99
UA - Ucraina 73
FI - Finlandia 68
IN - India 61
HK - Hong Kong 43
CH - Svizzera 31
IR - Iran 19
BE - Belgio 18
JP - Giappone 16
NL - Olanda 16
BR - Brasile 15
FR - Francia 13
CZ - Repubblica Ceca 10
PL - Polonia 10
AU - Australia 9
IL - Israele 7
KR - Corea 7
TW - Taiwan 7
CL - Cile 6
IE - Irlanda 6
PH - Filippine 6
GR - Grecia 5
ID - Indonesia 5
AR - Argentina 4
MX - Messico 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
CO - Colombia 3
EC - Ecuador 3
MY - Malesia 3
RS - Serbia 3
VE - Venezuela 3
BJ - Benin 2
BY - Bielorussia 2
EG - Egitto 2
ES - Italia 2
HU - Ungheria 2
IQ - Iraq 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 12.702
Salva come PNG Salva come JPEG
Città #
Woodbridge 658
Chandler 580
Fairfield 490
Santa Clara 450
Ann Arbor 403
Ashburn 393
Milan 357
Houston 304
Sofia 270
Seattle 214
Wilmington 208
Vienna 203
New York 196
Cambridge 181
Beijing 179
Singapore 178
Abidjan 146
Princeton 138
Boardman 129
Lawrence 106
Ottawa 105
Dakar 104
London 103
Florence 91
Jacksonville 91
Serra 85
Medford 80
Frankfurt am Main 61
Pisa 57
Izmir 56
Nanjing 56
Bremen 52
Dearborn 52
Istanbul 52
Des Moines 51
Boulder 50
Dong Ket 49
Rome 41
San Diego 37
Munich 36
Redmond 34
Fuzhou 33
Hong Kong 31
Shanghai 30
Lancaster 28
Bern 27
Los Angeles 26
Redwood City 25
Ogden 24
Nanchang 20
Washington 20
Quanzhou 18
Brussels 17
Guangzhou 16
Jiaxing 16
Dallas 14
Kunming 14
Jüchen 13
Changsha 12
Ningbo 11
Norwalk 11
Chiesina Uzzanese 10
Düsseldorf 10
Helsinki 10
Nürnberg 10
Shenyang 10
Vicopisano 10
Wuhan 10
Zhengzhou 10
Brno 9
Chengdu 9
Hefei 9
Kocaeli 9
Pune 9
Tianjin 9
Toronto 9
Hangzhou 8
Hebei 8
Philadelphia 8
Phoenix 8
Scandicci 8
Jinan 7
Falls Church 6
Grafing 6
Xiamen 6
Chicago 5
Pontedera 5
Salt Lake City 5
Samsun 5
San Francisco 5
Urmia 5
Amsterdam 4
Bratislava 4
City of Westminster 4
Dublin 4
Edinburgh 4
Marseille 4
Matsudo 4
Montreal 4
Naples 4
Totale 7.806
Salva come PNG Salva come JPEG
Nome #
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 201
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 200
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 196
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 195
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 189
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 182
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 180
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 177
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 169
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 169
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 167
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 159
Targeted Therapy in Thyroid Cancer: State of the Art 159
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 158
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 155
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 155
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 155
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 153
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 152
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 151
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 146
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 146
null 146
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 144
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 142
RET point mutations in Thyroid Carcinoma 142
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 142
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 142
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 135
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 133
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 132
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 131
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 129
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 129
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 127
Thyroid consequences of the Chernobyl nuclear accident. 127
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 127
Il carcinoma tiroideo: nuove prospettive terapeutiche. 127
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 126
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 126
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 125
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 123
null 122
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 121
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 121
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 120
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 119
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 119
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 119
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 118
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 117
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 116
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 115
Thyroid incidentaloma 114
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 114
null 114
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 113
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 113
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 111
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 110
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 108
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 108
null 107
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 106
null 105
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 104
null 103
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 102
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 100
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 99
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 99
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 97
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 95
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 93
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 93
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 93
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 91
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 90
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 89
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 88
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 87
null 86
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 85
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 85
null 84
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 80
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 74
null 70
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 69
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 68
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 68
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 65
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 64
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 62
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 62
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 61
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 61
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 60
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 58
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 57
Totale 11.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.444 0 0 0 0 0 254 249 113 151 270 374 33
2020/2021912 154 39 143 28 49 84 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.605 161 174 220 110 214 283 114 52 28 22 74 153
2024/20251.100 48 158 44 269 491 90 0 0 0 0 0 0
Totale 12.949